Skip To Main Content
Sree Appu on Muck Rack

Sree Appu

As seen in: Nature, European Urology
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile
Back to Sree Appu’s profile

Articles by Sree Appu

Dynamic immune profiling predicts response to radiation plus anti-PD-1 therapy in oligometastatic renal cell carcinoma

|
By Van To, Niko Thio, Rebecca G Castle, Sean MacDonald, Tristan Molden-Hauer, James Wells, Ryan McMahon, Mathias Bressel, Ben Tran, Arun A. Azad, Daniel Moon, Sree Appu, Lih-Ming Wong, Declan Murphy, David B. Pryor, Lavinia Spain, Lewis Au, Criselle D’Souza, Paul Neeson, Shankar Siva, Katharine Cuff
| Nature Verified
Abstract Biomarkers that predict response to combined radiation and anti-PD-1 therapy in clear cell renal cell carcinoma (ccRCC) are poorly defined. RAPPORT trial (NCT02855203) is a prospective phase I/II study of stereotactic ablative body radiotherapy (SABR) and pembrolizumab in 30 patients with oligometastatic ccRCC.
Open in Who Shared Issue with article?

Stereotactic Radiotherapy for Renal Cell Carcinoma: The Fallacy of (False) Positive Post-treatment Biopsy?

|
By Rohann J.M. Correa, Sree Appu, Shankar Siva
| European Urology Verified
Enthusiasm continues to build for the use of stereotactic ablative radiotherapy (SABR) for primary renal cell carcinoma (RCC), with evidence including several prospective clinical trials demonstrating excellent oncologic and renal function outcomes. In this issue of European Urology, Hannan and colleagues [] add to the rising tide of prospective evidence and provide novel post-treatment histology data on the nuances of cellular and transcriptomic changes after SABR.
Open in Who Shared Issue with article?
Show More